198 Appendices List of publications AAMT Donners, K van der Zwet, ACG Egberts, K Fijnvandraat, RAA Mathot, I Kruis, MH Cnossen, REG Schutgens, RT Urbanus, K Fischer. DosEmi study protocol: a phase IV, multicenter, open-label, crossover study to evaluate noninferiority of pharmacokineticguided reduced dosing compared with conventional dosing of emicizumab in persons with haemophilia A. Submitted. S Bansal, AAMT Donners, K Fischer, S Kshirsagar, S Rangarajan, V Phadke, S Mhatre, B Sontate, M D’silva, S Ansari, S Shetty. Low dose emicizumab prophylaxis in haemophilia A patients: a pilot study from India. Haemophilia (in press). AAMT Donners, K van der Zwet, CMA Rademaker, ACG Egberts, REG Schutgens, K Fischer. The efficacy of the entire-vial dosing of emicizumab: real-world evidence on plasma concentrations, bleeds and drug waste. Res Pract Thromb Haemost 2023; 7: e100074. AAMT Donners, L Gerencsér, KCM van der Elst, ACG Egberts, MPM de Maat, A Huisman, RT Urbanus, M El Amrani. Quantification of emicizumab by mass spectrometry in plasma of people with hemophilia A: A method validation study. Res Pract Thromb Haemost 2022; 6: e12725. AAMT Donners, CMA Rademaker, LAH Bevers, ADR Huitema, REG Schutgens, ACG Egberts, K Fischer. Pharmacokinetics and associated efficacy of emicizumab in humans: a systematic review. Clin Pharmacokinet 2021; 60: 1395-1406. L Bukkems, K Fischer, I Kremer-Hovinga, AAMT Donners, K Fijnvandraat, REG Schutgens, MH Cnossen, RAA Mathôt. Emicizumab dosing in children and adults with hemophilia a: simulating a user-friendly and cost-efficient regimen. Thromb Haemost 2022; 122: 208-215. AAMT Donners, EM van Maarseveen, YRJ Weetink, M El Amrani, K Fischer, CMA Rademaker, ACG Egberts, A Huisman, REA Musson. Vergelijking tussen factor VIII gemeten met een activiteitsassay en met massaspectrometrie bij patiënten met hemofilie A. Nederlands Platform voor Farmaceutisch Onderzoek 2020; 5: a1716. AAMT Donners, EM van Maarseveen, YRJ Weetink, M El Amrani, K Fischer, CMA Rademaker, ACG Egberts, A Huisman, REA Musson. Comparison between coagulation factor VIII quantified with one-stage activity assay and with mass spectrometry in haemophilia A patients: Proof of principle. Int J Lab Hematol 2020; 42: 819-826. M El Amrani, AAMT Donners, CE Hack, ADR Huitema, EM van Maarseveen. Six-step workflow for the quantification of therapeutic monoclonal antibodies in biological
RkJQdWJsaXNoZXIy MTk4NDMw